Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Allergan’s JUVEDERM XC treatment approved by FDA

Allergan’s JUVEDERM XC treatment approved by FDA

9th February 2010

Allergan, a provider of pharmacy products, has announced that the Food and Drug Administration (FDA) has approved its hyaluronic acid filler JUVEDERM XC.

A variation of the previously approved JUVEDERM, the product utilises the latest advancement in hyaluronic acid (HA) dermal fillers and contains the local anesthetic lidocaine to provide patients with enhanced comfort during treatment of moderate to severe facial wrinkles and folds.

JUVEDERM XC’s formulation features 0.3 per cent of the preservative-free lidocaine, which numbs the treatment area within seconds and provides the results as demonstrated with the existing formulation.

Robert Grant, Allergan’s corporate vice-president, said: “We lead innovation in the dermal filler category with the first and only smooth-consistency gel hyaluronic acid dermal filler approved by the FDA to last up to a year.”

In other Allergan news, last October the organisation announced that it was contesting a ruling that forbids it from sharing relevant information to assist physicians in evaluating the risks and benefits of Botox (onabotulinumtoxinA).

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.